Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,510.00
Bid: 12,524.00
Ask: 12,526.00
Change: 118.00 (0.95%)
Spread: 2.00 (0.016%)
Open: 12,468.00
High: 12,556.00
Low: 12,434.00
Prev. Close: 12,392.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-U.S. to send 4 mln doses of AstraZeneca vaccine to Mexico, Canada in loan deal -official

Thu, 18th Mar 2021 16:59

(Adds Psaki comment)

By Jeff Mason

WASHINGTON, March 18 (Reuters) - The United States plans to
send roughly 4 million doses of AstraZeneca's COVID-19 vaccine
that it is not using to Mexico and Canada in loan deals with the
two countries, an administration official told Reuters on
Thursday.

Mexico will receive 2.5 million doses of the vaccine and
Canada is to receive 1.5 million doses, the official said.

"We're lending a portion of our releasable doses of
AstraZeneca vaccine," the official said on condition of
anonymity. "We only put the virus behind us if we're helping our
global partners."

White House spokeswoman Jen Psaki confirmed the plan, first
reported by Reuters, to send doses to Mexico and Canada. "It is
not fully finalized yet but it is our aim," she told a daily
briefing.

The Biden administration has come under pressure from allies
worldwide to share vaccines, particularly from AstraZeneca,
which is authorized for use in other countries but not yet in
the United States.

AstraZeneca has millions of doses made in a U.S.
facility, and has said that it would have 30 million shots ready
at the beginning of April. The company's shares rose slightly on
the news.

The deal to share the vaccine, which is still being
finalized, does not affect President Joe Biden's plans to have
vaccine available for all adults in the United States by the end
of May, the official said. It does not reduce the supply of
available vaccine in the United States.

The deal is likely to be announced publicly in the coming
days.

Two officials said the vaccine would be delivered in "short
order" once the deal was completed, but they declined to give a
more specific timetable.

The "releasable" vaccines are ready to be used once they
arrive. Under the deal, the United States will share doses with
Mexico and Canada now with the understanding that they will pay
the United States back with doses in return. The official said
that would take place later this year.

The United States had no plans to share the vaccine with
other countries at this time, he said.

"They are our neighbors, they are our partners," the
official said about Mexico and Canada. Mexican President Andres
Manuel Lopez Obrador had requested the vaccine previously. The
official said the countries were in touch about the vaccine
loan. "We've been working through the diplomatic channels," he
said.

Reports of blood disorders have prompted more than a dozen
nations to suspend use of AstraZeneca's vaccine but on Thursday
the EU's drug watchdog said that after an investigation it is
still convinced the benefits of that vaccine outweigh the risks.

Biden has said if the United States has a surplus of
vaccine, it will share it with the rest of the world. The White
House has focused on vaccinating people in the United States,
which has seen more than 530,000 people die from virus.

The country was getting prepared to roll out the AstraZeneca
vaccine domestically if it gets authorization from the U.S. Food
and Drug Administration, the official said.

The official noted that the United States has pledged $4
billion to the COVAX vaccine facility that aims to deliver
coronavirus vaccines to poor countries.

The United States does not need the AstraZeneca shots to
meet its target of having enough doses for all U.S. adults by
the end of May.

The three authorized vaccine makers – Pfizer Inc/BioNTech
SE, Moderna Inc, and Johnson & Johnson – have promised to
deliver nearly 500 million doses to the United States by then.
(Reporting by Jeff Mason; additional reporting by Trevor
Hunnicutt and Caroline Humer; Editing by Heather Timmons and
Alistair Bell)

More News
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more
26 Feb 2024 08:51

AstraZeneca's Voydeya treatment recommended for EU approval

(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.

Read more
26 Feb 2024 07:22

AstraZeneca's blood-disorder drug recommended for EU approval

(Sharecast News) - European regulators has given the green light to AstraZeneca's blood-disorder drug Voydeya, the biopharma giant announced on Monday.

Read more
22 Feb 2024 17:36

EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track"

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and Thursday and not separately reported by Alliance News:

Read more
20 Feb 2024 10:29

AstraZeneca acquires US-based biopharmaceutical company

(Sharecast News) - Drugmaker AstraZeneca revealed late on Monday afternoon that it had successfully completed its acquisition of US-based biopharmaceutical company Icosavax.

Read more
20 Feb 2024 09:40

LONDON BROKER RATINGS: JPMorgan cuts Airtel Africa price target by 28%

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
19 Feb 2024 16:51

LONDON MARKET CLOSE: Europe lacks direction on quiet Monday

(Alliance News) - European markets lacked direction on Monday, after a quiet day as the US markets celebrated George Washington's birthday.

Read more
19 Feb 2024 15:59

London close: Stocks manage gains on globally quiet day

(Sharecast News) - London's financial markets finished in positive territory on Monday, with stocks closing in the green after overcoming minor losses earlier in the session.

Read more
19 Feb 2024 15:39

UPDATE: AstraZeneca completes USD1.1 billion acquisition of Icosavax

(Alliance News) - AstraZeneca PLC on Monday said it has completed the acquisition of Icosavax Inc.

Read more
19 Feb 2024 11:51

LONDON MARKET MIDDAY: Stocks lack direction amid quiet start to week

(Alliance News) - Stock prices in London lacked direction at midday Monday, amid a quiet start to the week.

Read more
19 Feb 2024 08:44

LONDON MARKET OPEN: Stocks drift; Currys surges on takeover interest

(Alliance News) - Stock prices in London were looking for direction early Monday, as investors weighed possible trajectories for US interest rate cuts and a China's economic recovery.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.